Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Babies with DiGeorge syndrome saved by immune supression, thymus transplant

04.08.2004


Duke University Medical Center researchers have developed a combination immune suppression and thymus transplantation technique to save infants born with complete DiGeorge Syndrome, a fatal genetic disorder.



Babies with complete DiGeorge Syndrome have no thymus, a gland important in the maturation of T cells -- specialized immune cells that help protect the body against viruses, bacteria and other pathogens. The thymus teaches T cells to fight infection while not attacking the infant’s own tissues.

Duke is the only center to offer thymus transplantation as a cure for the immune defect. Without this treatment, infants with complete DiGeorge syndrome are unable to fight off infections and will die.


Until recently, some babies with complete DiGeorge could not receive a thymus transplant because some of their bone marrow cells had spontaneously transformed into rogue T cells. These T cells attack both the body’s own tissues and foreign tissue, so thymus transplants would be rejected.

Building on 12 years of experience in treating DiGeorge syndrome, Louise Markert, M.D., associate professor of pediatrics at Duke University Medical Center, and her colleagues found that quashing the rogue T cells with an immunosuppressant drug given for three days immediately before transplant surgery resulted in successful thymus transplants. Five of six infants who underwent the new procedure survived and now live at home; one succumbed to a preexisting respiratory infection. "This really works for this population," Markert said. "It’s still experimental, but right now it’s the best option."

The immunosuppressant drug, called Thymoglobulin, only targets T cells, Markert said. "It’s less powerful than most chemotherapy. We really only need the T cells killed, and just long enough for the transplant," she said.

The transplant method and treatment results for the six infants with DiGeorge syndrome will appear in the Oct. 15, 2004, print issue of the journal Blood and are available online at the journal’s Web site, http://www.bloodjournal.org. The research was funded by the National Institutes of Health.

Not every child born with DiGeorge syndrome will need a thymus transplant. Milder forms of the disease occur in about one out of 4,000 births. Of those, only one in 250 babies -- between five and 10 each year in the U.S. -- will have complete DiGeorge syndrome with an absent thymus gland.

The disorder is often diagnosed initially by identifying birth defects characteristic of complete DiGeorge, including heart abnormalities, low calcium levels because of a missing parathyroid gland, esophageal defects and facial abnormalities such as low-set ears, wide-set eyes and a small jaw. The disorder can arise spontaneously or run in families. In less than half of cases, infants with complete DiGeorge syndrome will have a defect on chromosome 22.

Markert notes the diagnosis of complete DiGeorge has been missed in many cases because genetic testing for a defect on chromosome 22 yields a normal result, despite evidence of characteristic birth defects. This misleading finding can delay treatment, exposing an infant to risk of serious infection.

The ideal time for a thymus tissue transplant is within three months after birth, Markert said. "The key thing is to get it done before infections develop," she said.

The thymus tissue for transplant comes from tissue that would otherwise be discarded during cardiac surgery on donor infants less than six months old. Since an infant’s characteristically large thymus gland often obstructs access to the heart, in many operations surgeons must remove parts of the thymus to access the heart. Parents of the donor infants agree to donate the discarded tissue for a transplant. The clinicians culture the donor tissue for two weeks while performing testing to ensure that no diseases are transferred with the transplanted thymus tissue.

Pediatric surgeons working with Markert transplant thin strips of donor thymus tissue into a recipient infant’s thigh muscle, where it is most likely to develop a network of blood vessels to deliver nourishment and oxygen. After transplantation, immature white blood cells from the baby’s bone marrow migrate to the thymus tissue, where they are trained to differentiate between germs and the body’s own cells. About three or four months after transplantation, mature T cells emerge -- the final step toward a functioning immune system.

The transplant recipients stay in isolation rooms in Duke Hospital, either on the pediatric floor or at Duke’s General Clinical Research Center, funded by the National Center for Research Resources of the National Institutes of Health. Such isolation helps prevent infections from developing in the infant before mature T cells form.

So far, Markert has performed thymus transplants for 26 infants with complete DiGeorge syndrome, including the six who received the new immunosuppression treatment . "I learn something from each one that will make the treatment better for the next patient," she said.

Co-authors on the study include Duke colleagues Marilyn Alexieff; Jie Li; Marcella Sarzotti, Ph.D.; Daniel Ozaki; Blythe Devlin; Debra Sedlak; Gregory Sempowski, Ph.D.; Laura Hale, M.D.; Henry Rice, M.D.; Samuel Mahaffey, M.D.; and Michael Skinner, M.D.

Becky Oskin | EurekAlert!
Further information:
http://www.duke.edu
http://www.dukemednews.org

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>